A Phase 1/2 interventional study of bevacizumab and AG-013726 in Colorectal Neoplasms, sponsored by Pfizer. Completed at 107 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Colorectal Neoplasms by Pfizer — 6 open to participants now, 14 under way, 3 of them phase 3. Colorectal Neoplasms · Pfizer.
Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 15th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 1/2, and was the 14th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →6 of the 73 studies in Colorectal Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Canada, China and 7 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 27 · Phase 3 9 · Phase 4 2
First in 1999; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 72 across the 68 interventional studies, 1 across the 3 observational. Of the 58 that completed or were terminated, 28 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Colorectal Neoplasms by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
| NCT07909122PfizerReal-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies in Colorectal Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bevacizumab 5 mg/kg every 2 weeks + FOLFOX
Drug: bevacizumab
AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
Drug: AG-013726
AG-013736 5 mg bid starting dose + FOLFOX
Drug: AG-013736 (axitinib)
bevacizumab 5 mg/kg every 2 weeks
AG-013726 5 mg bid every 2 weeks
AG-013736 5 mg bid starting dose
Percentage of Participants With Objective Response: Phase 2
Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as \>=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.
Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
Time frame: Predose, 1, 2, 2.5, 4, 6 and 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞\] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1
PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Minimum Observed Plasma Trough Concentration (Cmin) For Axitinib: Phase 1
Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Apparent Oral Clearance (CL/F) For Axitinib: Phase 1
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1
PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Minimum Observed Plasma Trough Concentration (Cmin) For Oxaliplatin: Phase 1
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Clearance (CL) For Oxaliplatin: Phase 1
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1
PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Minimum Observed Plasma Trough Concentration (Cmin) For 5-Fluorouracil: Phase 1
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Clearance (CL) For 5-Fluorouracil: Phase 1
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1
Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Minimum Observed Plasma Trough Concentration (Cmin) For Irinotecan: Phase 1
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Clearance (CL) For Irinotecan: Phase 1
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1
PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Minimum Observed Plasma Trough Concentration (Cmin) For Bevacizumab: Phase 1
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Clearance (CL) For Bevacizumab: Phase 1
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Duration of Response (DR): Phase 2
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: \>=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Progression-Free Survival (PFS): Phase 2
Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Time to Treatment Failure (TTF): Phase 2
TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Overall Survival (OS): Phase 2
Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Every 3 months after discontinuation of study treatment until death due to any cause or 1 year after randomization of the last participant
Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2
PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was "at its worst". Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was "as bad as you can imagine" or "interfered completely" with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms.
Time frame: Cycle 1 Day 1 (baseline), every 2 weeks for the first 2 months (Cycle 2 Day 1 [C2D1], Cycle 3 Day 1, and Cycle 4 Day 1) then monthly thereafter starting Cycle 6 Day 1, and 28 days after the last dose
| Milestone | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFIRI (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 4 | 8 | 6 | 4 | 6 | 3 | 18 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 4 | 8 | 6 | 4 | 6 | 3 | 18 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 11 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 1 | 3 | 0 | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 3 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFIRI (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 43 | 41 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 | 43 | 41 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42 | 43 | 41 |
| Withdrew: Ongoing in study a4061008 (nct00828919) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 9 | 10 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 16 | 7 |
| Withdrew: Objective progression or relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 10 | 17 |
| Withdrew: Global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 4 | 5 |
| Withdrew: Randomized, but not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as \>=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.
| Percentage of participants | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Percentage of Participants With Objective Response: Phase 2 | 28.6 (15.7 to 44.6) | 48.8 (33.3 to 64.5) | 39.0 (24.2 to 55.5) |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
| nanogram hour per milliliter (ng*hr/mL) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 8 | 119.02 (56.17 to 252.21) | 106.76 (27.27 to 417.89) | 97.05 (49.01 to 192.16) |
| Cycle 2 Day 1 | 95.70 (45.16 to 202.80) | 143.68 (36.70 to 562.43) | 117.47 (59.32 to 232.60) |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞\] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 8 | 190.51 (77.99 to 465.35) | 113.20 (8.89 to 1442.19) | 205.41 (53.61 to 787.01) |
| Cycle 2 Day 1 | 224.46 (91.89 to 548.29) | 168.07 (13.19 to 2141.15) | 178.46 (46.58 to 683.73) |
PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.
| ng/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 8 | 35.57 (18.37 to 68.89) | 27.14 (7.40 to 99.49) | 24.23 (14.32 to 40.98) |
| Cycle 2 Day 1 | 27.51 (14.20 to 53.28) | 42.48 (11.59 to 155.73) | 32.62 (19.29 to 55.18) |
No measurements were reported for this outcome.
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.
| Liter per hour (L/hr) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 8 | 30.01 (15.05 to 59.82) | 47.10 (3.72 to 596.29) | 28.49 (9.32 to 87.03) |
| Cycle 2 Day 1 | 30.08 (15.09 to 59.96) | 33.33 (2.63 to 421.92) | 28.90 (9.46 to 88.31) |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.
| hours | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 8 | 3.26 ± 3.943 | 2.23 ± 0.702 | 3.47 ± 2.820 |
| Cycle 2 Day 1 | 6.12 ± 7.450 | 3.09 ± 0.889 | 1.73 ± 0.456 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|
| Cycle 1 Day 1 | 4814.87 (4079.46 to 5682.84) | 4308.71 (2822.77 to 6576.87) |
| Cycle 2 Day 1 | 5231.71 (4432.64 to 6174.83) | 5303.66 (3474.59 to 8095.57) |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|
| Cycle 1 Day 1 | 5955.70 (4615.41 to 7685.21) | 5137.31 (3296.14 to 8006.93) |
| Cycle 2 Day 1 | 6744.06 (5226.35 to 8702.50) | 6430.67 (4125.97 to 10022.74) |
PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.
| ng/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|
| Cycle 1 Day 1 | 278.81 (201.38 to 386.03) | 265.05 (67.62 to 1038.93) |
| Cycle 2 Day 1 | 318.99 (230.40 to 441.66) | 374.03 (95.42 to 1466.10) |
No measurements were reported for this outcome.
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| L/hr | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|
| Cycle 1 Day 1 | 27.51 (21.56 to 35.11) | 30.74 (18.48 to 51.13) |
| Cycle 2 Day 1 | 24.29 (19.04 to 31.00) | 24.56 (14.76 to 40.85) |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| hours | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|
| Cycle 1 Day 1 | 20.63 ± 6.513 | 18.38 ± 3.004 |
| Cycle 2 Day 1 | 23.30 ± 14.975 | 19.86 ± 4.110 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 1 | 39212.03 (22388.50 to 68677.39) | 40955.29 (23831.07 to 70384.39) | 52164.28 (4725.16 to 575877.57) |
| Cycle 2 Day 1 | 45087.71 (25743.27 to 78968.27) | 36533.84 (21258.32 to 62785.83) | 95123.13 (8616.47 to 1050129.94) |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 1 | 36314.14 (19623.50 to 67200.90) | 41460.50 (23968.34 to 71718.51) | 52430.15 (4751.38 to 578551.86) |
| Cycle 2 Day 1 | 38983.80 (21066.13 to 72141.23) | 36776.79 (21260.68 to 63616.60) | 96632.41 (8757.13 to 1066311.16) |
PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.
| ng/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 1 | 16160.85 (6975.82 to 37439.78) | 34436.94 (22763.46 to 52096.78) | 19622.74 (2754.12 to 139809.41) |
| Cycle 2 Day 1 | 16249.77 (7014.20 to 37645.79) | 39730.46 (26262.58 to 60104.90) | 34180.87 (4797.41 to 243534.09) |
No measurements were reported for this outcome.
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| L/hr | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 1 | 147.43 (77.38 to 280.93) | 128.28 (73.44 to 224.05) | 99.36 (10.18 to 969.40) |
| Cycle 2 Day 1 | 137.34 (72.08 to 261.70) | 144.62 (82.80 to 252.59) | 53.92 (5.53 to 526.06) |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| hours | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) |
|---|---|---|---|
| Cycle 1 Day 1 | 0.26 ± 0.218 | 0.19 ± 0.069 | 0.39 ± 0.291 |
| Cycle 2 Day 1 | 0.25 ± 0.142 | 0.14 ± 0.029 | 0.24 ± 0.131 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
| ng*hr/mL | Phase 1: Axitinib + FOLFIRI (Cohort 4) |
|---|---|
| Cycle 1 Day 1 | 12081.58 (8805.17 to 16577.15) |
| Cycle 2 Day 1 | 11496.32 (8378.62 to 15774.11) |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
| ng*hr/mL | Phase 1: Axitinib + FOLFIRI (Cohort 4) |
|---|---|
| Cycle 1 Day 1 | 13055.88 (9371.39 to 18188.96) |
| Cycle 2 Day 1 | 12459.89 (8943.60 to 17358.66) |
Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.
| ng/mL | Phase 1: Axitinib + FOLFIRI (Cohort 4) |
|---|---|
| Cycle 1 Day 1 | 1910.25 (1561.45 to 2336.97) |
| Cycle 2 Day 1 | 1788.69 (1462.08 to 2188.26) |
No measurements were reported for this outcome.
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| L/hr | Phase 1: Axitinib + FOLFIRI (Cohort 4) |
|---|---|
| Cycle 1 Day 8 | 26.09 (18.10 to 37.61) |
| Cycle 2 Day 1 | 27.34 (18.97 to 39.40) |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| hours | Phase 1: Axitinib + FOLFIRI (Cohort 4) |
|---|---|
| Cycle 1 Day 1 | 6.45 ± 1.406 |
| Cycle 2 Day 1 | 6.75 ± 0.886 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) |
|---|---|
| Cycle 1 Day 1 | 3394758.83 (2453600.72 to 4696928.65) |
| Cycle 2 Day 1 | 3554899.52 (2569344.23 to 4918496.49) |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
| ng*hr/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) |
|---|---|
| Cycle 1 Day 1 | 4987528.96 (3395240.62 to 7326563.24) |
| Cycle 2 Day 1 | 5114888.84 (3481940.36 to 7513651.92) |
PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.
| ng/mL | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) |
|---|---|
| Cycle 1 Day 1 | 26460.05 (19574.60 to 35767.50) |
| Cycle 2 Day 1 | 26850.12 (19863.16 to 36294.76) |
No measurements were reported for this outcome.
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| L/hr | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) |
|---|---|
| Cycle 1 Day 1 | 0.01 (0.01 to 0.02) |
| Cycle 2 Day 1 | 0.02 (0.01 to 0.02) |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.
| hours | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) |
|---|---|
| Cycle 1 Day 1 | 205.97 ± 46.454 |
| Cycle 2 Day 1 | 210.22 ± 55.317 |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: \>=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
| days | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Duration of Response (DR): Phase 2 | 434.0 (246.0 to 666.0) | NA (232.0 to NA) | 343.0 (168.0 to 490.0) |
Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
| days | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Progression-Free Survival (PFS): Phase 2 | 336 (225.0 to 749.0) | 485 (276.0 to NA) | 381 (238.0 to 425.0) |
TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.
| days | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Time to Treatment Failure (TTF): Phase 2 | 187.0 (162.0 to 315.0) | 241.0 (205.0 to 344.0) | 238.0 (155.0 to 333.0) |
Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| days | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Overall Survival (OS): Phase 2 | 552.0 (443.0 to 911.0) | 659.0 (493.0 to 899.0) | 601.0 (533.0 to 882.0) |
PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was "at its worst". Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was "as bad as you can imagine" or "interfered completely" with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms.
| units on scale | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|
| Severity Scale: Baseline (n=41,43,40) | 1.62 ± 1.57 | 2.20 ± 1.93 | 2.18 ± 2.06 |
| Severity Scale: C2D1 (n=37,37,37) | 0.63 ± 1.22 | 0.04 ± 1.16 | 0.80 ± 1.32 |
| Severity Scale: C3D1 (n=32,38,32) | 0.68 ± 1.29 | -0.22 ± 1.17 | 0.63 ± 1.61 |
| Severity Scale: C4D1 (n=23,37,30) | 0.88 ± 1.41 | -0.40 ± 1.27 | 0.64 ± 1.68 |
| Severity Scale: C5D1 (n=23,34,29) | 0.72 ± 1.37 | -0.34 ± 1.59 | 0.60 ± 2.13 |
| Severity Scale: C6D1 (n=15,38,26) | 0.70 ± 1.80 | 0.09 ± 1.44 | 0.96 ± 1.60 |
| Severity Scale: C7D1 (n=12,30,22) | 0.28 ± 1.51 | -0.16 ± 1.55 | 0.26 ± 1.22 |
| Severity Scale: C8D1 (n=17,29,22) | 0.28 ± 1.45 | -0.13 ± 1.56 | 0.42 ± 1.74 |
| Severity Scale: C9D1 (n=11,24,21) | -0.15 ± 1.55 | -0.03 ± 1.67 | 0.76 ± 1.50 |
| Severity Scale: C10D1 (n=14,27,21) | 0.28 ± 1.37 | 0.06 ± 1.52 | 0.77 ± 1.52 |
| Severity Scale: C11D1 (n=10,20,19) | 0.15 ± 1.57 | -0.05 ± 1.59 | 0.57 ± 1.33 |
| Severity Scale: C12D1 (n=11,23,16) | 0.32 ± 1.40 | 0.47 ± 1.37 | 0.38 ± 1.14 |
| Severity Scale: C13D1 (n=8,13,12) | -0.09 ± 1.43 | 0.10 ± 1.35 | 0.73 ± 1.55 |
| Severity Scale: C14D1 (n=8,17,14) | 0.03 ± 0.81 | 0.38 ± 1.48 | -0.05 ± 1.44 |
| Severity Scale: C15D1 (n=7,11,9) | 0.28 ± 1.50 | 0.42 ± 1.49 | 0.71 ± 1.34 |
| Severity Scale: C16D1 (n=7,17,14) | -0.30 ± 0.88 | 0.11 ± 1.46 | 0.05 ± 2.08 |
| Severity Scale: C17D1 (n=5,11,6) | -0.20 ± 0.70 | 0.21 ± 1.69 | 0.72 ± 1.07 |
| Severity Scale: C18D1 (n=6,14,9) | 0.02 ± 0.85 | 0.31 ± 1.15 | 0.61 ± 1.55 |
| Severity Scale: C19D1 (n=4,8,16) | -0.18 ± 0.54 | 0.34 ± 1.42 | 0.81 ± 2.32 |
| Severity Scale: C20D1 (n=5,14,8) | -0.06 ± 0.54 | 0.15 ± 1.21 | -0.06 ± 1.67 |
| Severity Scale: C21D1 (n=4,5,5) | -0.25 ± 0.71 | 0.27 ± 1.90 | 1.20 ± 1.35 |
| Severity Scale: C22D1 (n=3,11,8) | 0.57 ± 0.45 | 0.81 ± 0.95 | 0.09 ± 1.37 |
| Severity Scale: C23D1 (n=4,5,3) | 0.30 ± 0.80 | 0.64 ± 1.32 | 1.05 ± 1.11 |
| Severity Scale: C24D1 (n=5,11,7) | 0.91 ± 2.07 | 0.37 ± 1.10 | -0.20 ± 1.62 |
| Severity Scale: C25D1 (n=4,5,5) | 0.25 ± 0.96 | -0.03 ± 1.12 | -0.30 ± 1.63 |
| Severity Scale: C26D1 (n=4,6,7) | -0.05 ± 0.76 | 0.46 ± 0.72 | -0.13 ± 1.79 |
| Severity Scale: C27D1 (n=4,3,4) | -0.21 ± 0.65 | 0.07 ± 0.99 | 0.34 ± 2.70 |
| Severity Scale: C28D1 (n=4,5,7) | 0.12 ± 0.82 | 0.74 ± 1.01 | -0.43 ± 2.00 |
| Severity Scale: C29D1 (n=2,3,4) | 3.00 ± 2.12 | -0.14 ± 0.58 | -0.09 ± 2.51 |
| Severity Scale: C30D1 (n=3,6,3) | 1.05 ± 1.70 | 0.45 ± 1.05 | 0.64 ± 0.68 |
| Severity Scale: C31D1 (n=1,1,3) | -0.50 ± NA | -0.64 ± NA | 1.55 ± 1.69 |
| Severity Scale: C32D1 (n=2,4,4) | 0.11 ± 0.25 | 0.80 ± 0.93 | 1.29 ± 1.03 |
| Severity Scale: C33D1 (n=0,0,2) | NA ± NA | NA ± NA | 0.89 ± 1.26 |
| Severity Scale: C34D1 (n=2,4,3) | 0.04 ± 0.15 | 0.75 ± 0.89 | 0.43 ± 0.74 |
| Severity Scale: C35D1 (n=0,0,1) | NA ± NA | NA ± NA | 0.79 ± NA |
| Severity Scale: C36D1 (n=2,3,2) | 0.29 ± 0.51 | 1.24 ± 1.22 | -0.18 ± 0.25 |
| Severity Scale: C37D1 (n=0,1,0) | NA ± NA | 0.86 ± NA | NA ± NA |
| Severity Scale: C38D1 (n=2,2,1) | 0.13 ± 0.28 | 1.68 ± 1.97 | 0.86 ± NA |
| Severity Scale: C39D1 (n=0,1,0) | NA ± NA | 0.86 ± NA | NA ± NA |
| Severity Scale: C40D1 (n=2,2,2) | 0.18 ± 0.35 | 1.29 ± 1.11 | 0.43 ± 0.61 |
| Severity Scale: C42D1 (n=2,2,1) | 0.18 ± 0.35 | 1.25 ± 1.26 | 0.00 ± NA |
| Severity Scale: Follow_Up (n=4,15,14) | 1.29 ± 2.75 | -0.00 ± 1.66 | 0.29 ± 1.72 |
| Interference Scale: Baseline (n=41,43,40) | 2.50 ± 2.70 | 2.79 ± 2.57 | 2.47 ± 2.66 |
| Interference Scale: C2D1 (n=37,37,36) | 0.46 ± 1.80 | -0.08 ± 1.74 | 0.78 ± 2.55 |
| Interference Scale: C3D1 (n=31,38,30) | 0.60 ± 2.37 | -0.57 ± 1.88 | 1.09 ± 2.37 |
| Interference Scale: C4D1 (n=23,36,30) | 0.92 ± 2.16 | -0.54 ± 1.89 | 1.15 ± 2.37 |
| Interference Scale: C5D1 (n=23,34,29) | 0.65 ± 2.20 | -0.59 ± 1.98 | 1.19 ± 2.90 |
| Interference Scale: C6D1 (n=15,38,26) | 0.32 ± 2.01 | -0.18 ± 2.33 | 0.99 ± 2.54 |
| Interference Scale: C7D1 (n=12,30,22) | 0.43 ± 1.25 | -0.59 ± 2.13 | 0.55 ± 2.05 |
| Interference Scale: C8D1 (n=17,29,22) | 0.01 ± 1.58 | -0.10 ± 2.00 | 0.48 ± 1.87 |
| Interference Scale: C9D1 (n=11,24,21) | -0.14 ± 1.08 | -0.39 ± 2.31 | 0.75 ± 1.76 |
| Interference Scale: C10D1 (n=14,27,21) | -0.18 ± 1.80 | 0.15 ± 2.06 | 0.99 ± 2.12 |
| Interference Scale: C11D1 (n=10,20,19) | 0.42 ± 1.23 | -0.51 ± 1.75 | 0.84 ± 2.50 |
| Interference Scale: C12D1 (n=10,23,16) | 0.03 ± 0.78 | 0.17 ± 2.23 | 0.38 ± 1.51 |
| Interference Scale: C13D1 (n=8,13,12) | -0.50 ± 1.56 | -0.31 ± 2.49 | 0.31 ± 1.70 |
| Interference Scale: C14D1 (n=8,17,14) | -0.10 ± 0.84 | 0.15 ± 2.57 | 0.29 ± 2.12 |
| Interference Scale: C15D1 (n=7,11,9) | -0.52 ± 0.85 | 0.27 ± 1.91 | 0.70 ± 2.36 |
| Interference Scale: C16D1 (n=7,17,14) | -0.02 ± 0.33 | -0.48 ± 2.31 | -0.01 ± 2.38 |
| Interference Scale: C17D1 (n=5,11,6) | -0.90 ± 1.31 | -0.29 ± 3.16 | 1.17 ± 1.28 |
| Interference Scale: C18D1 (n=6,14,9) | 0.06 ± 0.34 | 0.04 ± 2.38 | 1.00 ± 2.26 |
| Interference Scale: C19D1 (n=4,8,6) | 0.04 ± 0.34 | 0.54 ± 2.25 | 1.04 ± 1.84 |
| Interference Scale: C20D1 (n=5,14,8) | 0.27 ± 0.65 | -0.08 ± 2.34 | 0.35 ± 2.07 |
| Interference Scale: C21D1 (n=4,5,5) | -0.04 ± 0.86 | -0.97 ± 3.50 | 1.83 ± 1.28 |
| Interference Scale: C22D1 (n=3,11,8) | 0.44 ± 0.84 | 0.74 ± 1.71 | 0.83 ± 2.05 |
| Interference Scale: C23D1 (n=4,5,3) | 0.21 ± 0.42 | 1.13 ± 2.58 | 1.28 ± 1.80 |
| Interference Scale: C24D1 (n=5,11,7) | 2.00 ± 3.25 | 0.30 ± 2.65 | 0.55 ± 2.33 |
| Interference Scale: C25D1 (n=4,5,5) | 0.00 ± 0.41 | 0.10 ± 2.45 | 0.90 ± 0.88 |
| Interference Scale: C26D1 (n=4,6,7) | 0.33 ± 0.85 | 0.67 ± 1.80 | 0.33 ± 2.11 |
| Interference Scale: C27D1 (n=4,3,4) | 0.04 ± 0.52 | 0.11 ± 1.13 | 1.63 ± 2.44 |
| Interference Scale: C28D1 (n=4,5,7) | 0.71 ± 1.19 | 0.97 ± 1.81 | 0.19 ± 2.40 |
| Interference Scale: C29D1 (n=2,3,4) | 3.25 ± 3.89 | -0.56 ± 0.96 | 1.33 ± 2.97 |
| Interference Scale: C30D1 (n=3,6,3) | 0.94 ± 1.49 | 1.08 ± 2.16 | 1.06 ± 1.83 |
| Interference Scale: C31D1 (n=1,1,3) | 0.00 ± NA | -0.17 ± NA | 2.33 ± 2.08 |
| Interference Scale: C32D1 (n=2,4,4) | 0.08 ± 0.12 | 1.50 ± 2.26 | 2.17 ± 1.81 |
| Interference Scale: C33D1 (n=0,0,2) | NA ± NA | NA ± NA | 1.92 ± 2.71 |
| Interference Scale: C34D1 (n=2,4,3) | 0.17 ± 0.24 | 1.25 ± 1.89 | 1.11 ± 1.51 |
| Interference Scale: C35D1 (n=0,0,1) | NA ± NA | NA ± NA | 1.67 ± NA |
| Interference Scale: C36D1 (n=2,3,2) | 0.17 ± 0.24 | 1.89 ± 2.18 | 1.33 ± 1.89 |
| Interference Scale: C37D1 (n=0,1,0) | NA ± NA | 0.83 ± NA | NA ± NA |
| Interference Scale: C38D1 (n=2,2,1) | 0.08 ± 0.12 | 2.25 ± 2.47 | -0.17 ± NA |
| Interference Scale: C39D1 (n=0,1,0) | NA ± NA | 0.50 ± NA | NA ± NA |
| Interference Scale: C40D1 (n=2,2,2) | 0.42 ± 0.59 | 2.50 ± 2.12 | 0.25 ± 0.35 |
| Interference Scale: C42D1 (n=2,2,1) | 0.25 ± 0.35 | 2.58 ± 2.24 | 0.00 ± NA |
| Interference Scale: Follow Up (n=4,15,14) | 1.33 ± 2.48 | -0.21 ± 2.44 | 0.91 ± 1.65 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1) | — | 3/6 (50%) | 6/6 (100%) |
| Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2) | — | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3) | — | 2/4 (50%) | 4/4 (100%) |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | — | 3/8 (37.5%) | 8/8 (100%) |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | — | 5/6 (83.3%) | 6/6 (100%) |
| Phase 1: Axitinib + FOLFIRI (Cohort 6) | — | 1/4 (25%) | 4/4 (100%) |
| Phase 1: Axitinib + FOLFOX (Cohort 7) | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase 1: Axitinib + FOLFIRI (Cohort 8) | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1: Axitinib + FOLFOX (Cohort 9) | — | 8/18 (44.4%) | 18/18 (100%) |
| Phase 2: Axitinib + FOLFOX | — | 15/39 (38.5%) | 39/39 (100%) |
| Phase 2: Bevacizumab + FOLFOX | — | 17/43 (39.5%) | 42/43 (97.7%) |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | — | 23/41 (56.1%) | 39/41 (95.1%) |
| Event | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1) | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2) | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFOX (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal infectionInfections and infestations | 0/6 | 0/6 | 0/4 | 0/8 | 0/6 | 0/4 | 0/6 | 1/3 | 1/18 | 1/39 | 0/43 | 0/41 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 2/6 | 0/4 | 0/8 | 2/6 | 0/4 | 0/6 | 0/3 | 0/18 | 3/39 | 2/43 | 7/41 |
| Diverticular perforationGastrointestinal disorders | 0/6 | 0/6 | 1/4 | 0/8 | 0/6 | 0/4 | 0/6 | 0/3 | 0/18 | 0/39 | 0/43 | 0/41 |
| Chest painGeneral disorders | 0/6 | 0/6 | 1/4 | 0/8 | 0/6 | 0/4 | 0/6 | 0/3 | 0/18 | 0/39 | 1/43 | 2/41 |
| CholecystitisHepatobiliary disorders | 0/6 | 0/6 | 0/4 | 0/8 | 1/6 | 1/4 | 0/6 | 0/3 | 0/18 | 0/39 | 0/43 | 0/41 |
| CholelithiasisHepatobiliary disorders | 0/6 | 0/6 | 0/4 | 0/8 | 0/6 | 1/4 | 0/6 | 0/3 | 0/18 | 0/39 | 0/43 | 0/41 |
| Abscess intestinalInfections and infestations | 0/6 | 0/6 | 1/4 | 0/8 | 0/6 | 0/4 | 0/6 | 0/3 | 0/18 | 0/39 | 0/43 | 0/41 |
| Deep vein thrombosisVascular disorders | 0/6 | 0/6 | 1/4 | 0/8 | 1/6 | 0/4 | 0/6 | 0/3 | 0/18 | 2/39 | 1/43 | 2/41 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/4 | 0/8 | 0/6 | 0/4 | 0/6 | 0/3 | 0/18 | 0/39 | 0/43 | 0/41 |
| BradycardiaCardiac disorders | 1/6 | 0/6 | 0/4 | 0/8 | 0/6 | 0/4 | 0/6 | 0/3 | 0/18 | 1/39 | 0/43 | 0/41 |
| Event | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1) | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2) | Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFOX (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/6 | 4/6 | 3/4 | 5/8 | 5/6 | 3/4 | 5/6 | 3/3 | 13/18 | 22/39 | 23/43 | 23/41 |
| VomitingGastrointestinal disorders | 3/6 | 3/6 | 1/4 | 5/8 | 0/6 | 1/4 | 2/6 | 3/3 | 6/18 | 12/39 | 12/43 | 15/41 |
| FatigueGeneral disorders | 5/6 | 4/6 | 4/4 | 4/8 | 3/6 | 4/4 | 4/6 | 2/3 | 14/18 | 24/39 | 29/43 | 31/41 |
| Mucosal inflammationGeneral disorders | 6/6 | 2/6 | 1/4 | 2/8 | 4/6 | 2/4 | 1/6 | 1/3 | 6/18 | 7/39 | 9/43 | 15/41 |
| Back painMusculoskeletal and connective tissue disorders | 2/6 | 1/6 | 0/4 | 0/8 | 1/6 | 1/4 | 1/6 | 3/3 | 4/18 | 6/39 | 3/43 | 6/41 |
| Neuropathy peripheralNervous system disorders | 3/6 | 2/6 | 4/4 | 0/8 | 2/6 | 0/4 | 4/6 | 0/3 | 5/18 | 12/39 | 23/43 | 17/41 |
| HypertensionVascular disorders | 6/6 | 3/6 | 4/4 | 2/8 | 2/6 | 2/4 | 2/6 | 2/3 | 8/18 | 16/39 | 8/43 | 26/41 |
| Decreased appetiteMetabolism and nutrition disorders | 5/6 | 4/6 | 2/4 | 4/8 | 4/6 | 0/4 | 3/6 | 1/3 | 5/18 | 10/39 | 10/43 | 20/41 |
| DehydrationMetabolism and nutrition disorders | 5/6 | 0/6 | 0/4 | 4/8 | 3/6 | 0/4 | 1/6 | 1/3 | 3/18 | 7/39 | 8/43 | 12/41 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 0/6 | 2/4 | 1/8 | 2/6 | 3/4 | 1/6 | 1/3 | 5/18 | 9/39 | 9/43 | 12/41 |
| Age, Customized(Participants) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFIRI (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Less than (<) 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 to 44 years | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 4 | 8 | 21 |
| 45 to 64 years | 2 | 1 | 3 | 3 | 2 | 1 | 5 | 3 | 13 | 22 | 18 | 23 | 96 |
| Greater than or equal to (>=) 65 years | 3 | 3 | 1 | 4 | 3 | 2 | 1 | 0 | 4 | 18 | 21 | 10 | 70 |
| Sex: Female, Male(Participants) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2) | Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3) | Phase 1: Axitinib + FOLFIRI (Cohort 4) | Phase 1: Axitinib + FOLFOX (Cohort 5) | Phase 1: Axitinib + FOLFIRI (Cohort 6) | Phase 1: Axitinib + FOLFOX (Cohort 7) | Phase 1: Axitinib + FOLFIRI (Cohort 8) | Phase 1: Axitinib + FOLFIRI (Cohort 9) | Phase 2: Axitinib + FOLFOX | Phase 2: Bevacizumab + FOLFOX | Phase 2: Axitinib + Bevacizumab + FOLFOX | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 2 | 2 | 1 | 2 | 2 | 0 | 7 | 17 | 15 | 15 | 67 |
| Male | 3 | 5 | 2 | 6 | 5 | 2 | 4 | 3 | 11 | 25 | 28 | 26 | 120 |
Showing the first 100 of 107 sites. Choose a country and city above to see the rest.
The record gives a start of Jan 2006, a primary completion of Apr 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib